MA-NETCRACKER-TECHNOLOGY
11.6.2020 15:12:12 CEST | Business Wire | Press release
Netcracker Technology announced today its Enhanced Security Plan, a holistic, multi-pronged framework of security solutions and services that are unmatched in the industry. As an integral part of the new Netcracker 2020 portfolio suite of products and services, Netcracker Enhanced Security gives service providers confidence in the security and privacy of their rapidly evolving networks, including 5G and multi-cloud environments, and the sensitive information of their customers.
“We believe the Netcracker Enhanced Security Plan is a model of good security practices,” stated Adam Hickey, Deputy Assistant Attorney General, National Security Division, U.S. Department of Justice.
As networks become more complex, including increased support for virtualization and IoT, data security and privacy become more critical. Netcracker Enhanced Security capabilities are designed to ensure that the entire lifecycle of developing, delivering, and operating business support system and operations support system platforms is secure. These capabilities include secure development processes, secure integration APIs, control and monitoring of platform access through a secure enclave infrastructure, strict change control policies and strong governance, including strong access control, frequent audits and regular security testing. Most importantly, the Netcracker Enhanced Security Plan controls how and where data is stored and accessed, enables anonymization of sensitive data, and is engineered to prohibit unauthorized access.
This combination of industry-leading technology and security protocols gives service providers around the world confidence that their mission-critical platforms are developed, implemented, and managed in a secure manner by Netcracker, enabling them to build trust with their customers and instill confidence that their sensitive information will be protected.
“Increased cybersecurity is critical as business models and technology change how service providers operate,” said Joel Brenner, former Inspector General of the National Security Agency and Head of U.S. Counterintelligence in the Office of the Director of National Intelligence, and current Senior Research Fellow at the MIT Center for International Studies. “The telecommunications industry must demand vendors follow strict security protocols to ensure restricted access to their most sensitive data and infrastructure.”
"We are pleased Netcracker has agreed to invest in enhanced security protocols that will reduce the risk of unauthorized access to its clients’ sensitive data,” said Dana Boente, Former Acting United States Attorney General. “As threats to our critical infrastructure increase, especially from abroad, these protocols serve as a model for the kind of security that U.S. critical infrastructure should expect from the firms they use to develop, install and maintain technology in their networks.”
“Netcracker’s Enhanced Security sets the standard for best security practices in the telecommunications industry,” said Samuel Visner, Security Director at Netcracker and former Chief of Signals Intelligence Programs at the U.S. National Security Agency. “Netcracker’s technology enriches the ability of service providers to support their own end users securely, even as more complex networks present us with a more significant cybersecurity challenge.”
About Netcracker Technology
Netcracker Technology, a wholly owned subsidiary of NEC Corporation, offers mission-critical digital transformation solutions to service providers around the globe. Our comprehensive portfolio of software solutions and professional services enables large-scale digital transformations, unlocking the opportunities of the cloud, virtualization and the changing mobile ecosystem. With an unbroken service delivery track record of more than 25 years, our unique combination of technology, people and expertise helps companies transform their networks and enable better experiences for their customers.
For more information, visit www.netcracker.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005503/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
